摘要
慢性丙型肝炎的标准化治疗为聚乙二醇化干扰素联合利巴韦林,其疗效欠佳,而口服直接抗病毒药物的问世给患者带来了新的希望。本文对美国感染病学会和美国肝病学会联合发布的抗HCV指南进行了分析及解读。
Pegylated-interferon combined with ribavirin is considered as the standard treatment of chronic hepatitis C. However, the efifcacy is limited and direct-acting antiviral agents advent brings new hope for patients infected with HCV. This paper aimed to analyze 2014 IDSA and ASSLD Guidelines for anti-hepatitis C virus.
出处
《中华实验和临床感染病杂志（电子版）》
CAS
2015年第4期5-9,共5页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
基金
国家自然科学基金(No.81371867)
江苏省医学科技专项-新型临床诊疗技术攻关(BL2014033)
江苏省"科教兴卫"医学重点人才培养基金(No.RC2011117)
江苏省"六大人才高峰"项目(No.2011-WS-068)
